Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond

For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with miss...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ursula Vogl [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Übergeordnetes Werk:	In: healthbook TIMES. Oncology Hematology - THE HEALTHBOOK COMPANY LTD., 2022, 9(2021), 3
Übergeordnetes Werk:	volume:9 ; year:2021 ; number:3

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.36000/hbT.OH.2021.09.046

Katalog-ID:	DOAJ08663187X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ08663187X
003	DE-627
005	20240413120804.0
007	cr uuu---uuuuu
008	230311s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.36000/hbT.OH.2021.09.046 \|2 doi
035			\|a (DE-627)DOAJ08663187X
035			\|a (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Ursula Vogl \|e verfasserin \|4 aut
245	1	0	\|a Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.
653		0	\|a Medicine
653		0	\|a R
773	0	8	\|i In \|t healthbook TIMES. Oncology Hematology \|d THE HEALTHBOOK COMPANY LTD., 2022 \|g 9(2021), 3 \|w (DE-627)1786544288 \|w (DE-600)3106733-5 \|x 26732106 \|7 nnns
773	1	8	\|g volume:9 \|g year:2021 \|g number:3
856	4	0	\|u https://doi.org/10.36000/hbT.OH.2021.09.046 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 \|z kostenfrei
856	4	0	\|u https://doi.org/10.36000/hbT.OH.2021.09.046 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2673-2092 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2673-2106 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2021 \|e 3

Indexfelder

author_variant	u v uv
matchkey_str	article:26732106:2021----::rteilacnmotmlramnotosn
hierarchy_sort_str	2021
publishDate	2021
allfields	10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3
spelling	10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3
allfields_unstemmed	10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3
allfieldsGer	10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3
allfieldsSound	10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3
language	English
source	In healthbook TIMES. Oncology Hematology 9(2021), 3 volume:9 year:2021 number:3
sourceStr	In healthbook TIMES. Oncology Hematology 9(2021), 3 volume:9 year:2021 number:3
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Medicine R
isfreeaccess_bool	true
container_title	healthbook TIMES. Oncology Hematology
authorswithroles_txt_mv	Ursula Vogl @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	1786544288
id	DOAJ08663187X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08663187X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413120804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.36000/hbT.OH.2021.09.046</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08663187X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ursula Vogl</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">healthbook TIMES. Oncology Hematology</subfield><subfield code="d">THE HEALTHBOOK COMPANY LTD., 2022</subfield><subfield code="g">9(2021), 3</subfield><subfield code="w">(DE-627)1786544288</subfield><subfield code="w">(DE-600)3106733-5</subfield><subfield code="x">26732106</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2092</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2106</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield></datafield></record></collection>
author	Ursula Vogl
spellingShingle	Ursula Vogl misc Medicine misc R Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
authorStr	Ursula Vogl
ppnlink_with_tag_str_mv	@@773@@(DE-627)1786544288
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	26732106
topic_title	Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
topic	misc Medicine misc R
topic_unstemmed	misc Medicine misc R
topic_browse	misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	healthbook TIMES. Oncology Hematology
hierarchy_parent_id	1786544288
hierarchy_top_title	healthbook TIMES. Oncology Hematology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1786544288 (DE-600)3106733-5
title	Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
ctrlnum	(DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6
title_full	Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
author_sort	Ursula Vogl
journal	healthbook TIMES. Oncology Hematology
journalStr	healthbook TIMES. Oncology Hematology
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
author_browse	Ursula Vogl
container_volume	9
format_se	Elektronische Aufsätze
author-letter	Ursula Vogl
doi_str_mv	10.36000/hbT.OH.2021.09.046
title_sort	urothelial carcinoma: optimal treatment options in first-line and beyond
title_auth	Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
abstract	For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.
abstractGer	For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.
abstract_unstemmed	For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
url	https://doi.org/10.36000/hbT.OH.2021.09.046 https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 https://doaj.org/toc/2673-2092 https://doaj.org/toc/2673-2106
remote_bool	true
ppnlink	1786544288
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.36000/hbT.OH.2021.09.046
up_date	2024-07-03T21:51:19.316Z
_version_	1803596311371448321
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08663187X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413120804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.36000/hbT.OH.2021.09.046</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08663187X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ursula Vogl</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">healthbook TIMES. Oncology Hematology</subfield><subfield code="d">THE HEALTHBOOK COMPANY LTD., 2022</subfield><subfield code="g">9(2021), 3</subfield><subfield code="w">(DE-627)1786544288</subfield><subfield code="w">(DE-600)3106733-5</subfield><subfield code="x">26732106</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2092</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2106</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield></datafield></record></collection>
score	7.3985615

Nicht das Richtige dabei?

Schreiben Sie uns!

Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?